Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nontypeable Haemophilus influenzae (NTHi) is a Gram-negative, non-encapsulated bacterium that serves as a major human pathogen, particularly in the context of respiratory tract infections (King, 2012). The "other surface antigens" of NTHi encompass a broad array of outer membrane proteins (OMPs) and surface-exposed molecules, such as P6, Omp26, and various adhesins, which are critical for the organism's pathogenicity (Murphy, 2003). These antigens facilitate essential biological processes including adherence to host epithelial cells, biofilm formation, and evasion of host immune defenses (Pichichero, 2013). In clinical medicine, these surface antigens are primary targets for the development of vaccines aimed at preventing otitis media in children and reducing the frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD) (Wilkinson et al., 2009). Therapeutic strategies focus on eliciting a robust humoral immune response, specifically opsonophagocytic antibodies that enhance bacterial clearance and prevent colonization of the respiratory tract (Murphy, 2003). Unlike the capsular antigens of typeable strains, these surface proteins exhibit varying degrees of conservation, making the selection of broadly protective antigens a significant challenge in vaccine design (Pichichero, 2013). Current research also explores the use of these antigens in diagnostic assays to monitor infection and vaccine efficacy (Wilkinson et al., 2009).
Vaccine-mediated induction of opsonophagocytic and bactericidal antibodies that prevent bacterial attachment to the respiratory mucosa and facilitate clearance by immune cells (Murphy, 2003; Pichichero, 2013).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Other surface antigens of nontypeable Haemophilus influenzae (NTHi OMPs).